CYTOPROTECTIVE THERAPY POTENTIAL IN PATIENTS WITH CHRONIC COR PULMONALE
The study investigated effectiveness and safety of a cytoprotector mexicor in patients with chronic cor pulmonale (CCP). All participants (n=56; age 38-80 years) were divided into four groups. Group I (n=16) received a standard pulmonary therapy, while Group II (n=20) also received mexicor (300 mg/d...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2010-10-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1495 |
| _version_ | 1797857179647082496 |
|---|---|
| author | S. A. Surotkina A. A. Kotlyarov N. M. Selezneva E. N. Efremova |
| author_facet | S. A. Surotkina A. A. Kotlyarov N. M. Selezneva E. N. Efremova |
| author_sort | S. A. Surotkina |
| collection | DOAJ |
| description | The study investigated effectiveness and safety of a cytoprotector mexicor in patients with chronic cor pulmonale (CCP). All participants (n=56; age 38-80 years) were divided into four groups. Group I (n=16) received a standard pulmonary therapy, while Group II (n=20) also received mexicor (300 mg/d intravenously, for 10 days), Group III (n=10) received a standard therapy plus verapamil (80-240 mg/d for 10 days), and Group IV (n=11) was administered intravenous mexicor (300 mg/d) plus verapamil (80-240 mg/d) for 10 days. All participants underwent daily measurement of blood pressure and heart rate, 6-minute walk test, spirography, Holter ECG monitoring, echocardiography, and colour Doppler ultrasound of common and internal carotid arteries. Adding mexicor to the standard therapy of CCP patients increased treatment effectiveness for the leading pathology, as well as for co-morbidities (heart failure, cardiac arrhythmias). Additionally, in these patients, mexicor improved effectiveness and safety of verapamil treatment, increasing its antihypertensive and antiarrythmic activity and reducing its negative effects on intracardiac hemodynamics. |
| first_indexed | 2024-04-09T20:52:29Z |
| format | Article |
| id | doaj.art-bf1082c7442c4cea9ad2f1f867ffff5e |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:52:29Z |
| publishDate | 2010-10-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-bf1082c7442c4cea9ad2f1f867ffff5e2023-03-29T21:23:17Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202010-10-010557631282CYTOPROTECTIVE THERAPY POTENTIAL IN PATIENTS WITH CHRONIC COR PULMONALES. A. Surotkina0A. A. Kotlyarov1N. M. Selezneva2E. N. Efremova3Кафедра госпитальной терапии, медицинский институт, ГОУ ВПО “МГУ им Н.П.Огарева”, СаранскКафедра госпитальной терапии, медицинский институт, ГОУ ВПО “МГУ им Н.П.Огарева”, СаранскКафедра госпитальной терапии, медицинский институт, ГОУ ВПО “МГУ им Н.П.Огарева”, СаранскКафедра госпитальной терапии, медицинский институт, ГОУ ВПО “МГУ им Н.П.Огарева”, СаранскThe study investigated effectiveness and safety of a cytoprotector mexicor in patients with chronic cor pulmonale (CCP). All participants (n=56; age 38-80 years) were divided into four groups. Group I (n=16) received a standard pulmonary therapy, while Group II (n=20) also received mexicor (300 mg/d intravenously, for 10 days), Group III (n=10) received a standard therapy plus verapamil (80-240 mg/d for 10 days), and Group IV (n=11) was administered intravenous mexicor (300 mg/d) plus verapamil (80-240 mg/d) for 10 days. All participants underwent daily measurement of blood pressure and heart rate, 6-minute walk test, spirography, Holter ECG monitoring, echocardiography, and colour Doppler ultrasound of common and internal carotid arteries. Adding mexicor to the standard therapy of CCP patients increased treatment effectiveness for the leading pathology, as well as for co-morbidities (heart failure, cardiac arrhythmias). Additionally, in these patients, mexicor improved effectiveness and safety of verapamil treatment, increasing its antihypertensive and antiarrythmic activity and reducing its negative effects on intracardiac hemodynamics.https://russjcardiol.elpub.ru/jour/article/view/1495mexicorverapamilchronic heart failurelung function |
| spellingShingle | S. A. Surotkina A. A. Kotlyarov N. M. Selezneva E. N. Efremova CYTOPROTECTIVE THERAPY POTENTIAL IN PATIENTS WITH CHRONIC COR PULMONALE Российский кардиологический журнал mexicor verapamil chronic heart failure lung function |
| title | CYTOPROTECTIVE THERAPY POTENTIAL IN PATIENTS WITH CHRONIC COR PULMONALE |
| title_full | CYTOPROTECTIVE THERAPY POTENTIAL IN PATIENTS WITH CHRONIC COR PULMONALE |
| title_fullStr | CYTOPROTECTIVE THERAPY POTENTIAL IN PATIENTS WITH CHRONIC COR PULMONALE |
| title_full_unstemmed | CYTOPROTECTIVE THERAPY POTENTIAL IN PATIENTS WITH CHRONIC COR PULMONALE |
| title_short | CYTOPROTECTIVE THERAPY POTENTIAL IN PATIENTS WITH CHRONIC COR PULMONALE |
| title_sort | cytoprotective therapy potential in patients with chronic cor pulmonale |
| topic | mexicor verapamil chronic heart failure lung function |
| url | https://russjcardiol.elpub.ru/jour/article/view/1495 |
| work_keys_str_mv | AT sasurotkina cytoprotectivetherapypotentialinpatientswithchroniccorpulmonale AT aakotlyarov cytoprotectivetherapypotentialinpatientswithchroniccorpulmonale AT nmselezneva cytoprotectivetherapypotentialinpatientswithchroniccorpulmonale AT enefremova cytoprotectivetherapypotentialinpatientswithchroniccorpulmonale |